Iluvatar CoreX plans HK$7.07 billion H-share placement at 15% discount to fund supply-chain and R&D push

Bulletin Express07-09

Shanghai-based AI-chip specialist Iluvatar CoreX has signed a placing agreement with Goldman Sachs (Asia), Morgan Stanley Asia, Huatai Financial and J.P. Morgan Securities to issue up to 14.86 million new H shares at HK$476.00 each. The deal, announced before Hong Kong trading hours on 9 July 2026, will be executed on a best-efforts basis to at least six institutional investors.

The offer price represents a 15.00% discount to the 8 July closing price of HK$560.00 and a 19.42% discount to the five-day average of HK$590.70. If fully placed, the transaction will raise gross proceeds of about HK$7.07 billion and net proceeds of roughly HK$7.03 billion, implying a net issue price of HK$473.41 per share.

The 14.86 million new shares equal 6.06% of Iluvatar CoreX’s outstanding H-share capital and 5.84% of total shares pre-issue, diluting existing shareholders to 5.52% of the enlarged share base of 269.17 million shares. Placees are expected to remain below the substantial-shareholder threshold. The placement will use 29.21% of the company’s 20% general mandate approved at the June 2026 AGM; no further shareholder vote is required.

Use of proceeds (target completion by end-2027): • 60% (HK$4.22 billion): strategic procurement and supply-chain resilience for critical components. • 15% (HK$1.06 billion): accelerated iteration of current GPGPU products and R&D for next-generation chips. • 10% (HK$703.35 million): expansion of full-stack software platforms, developer ecosystem and industry-specific AI solutions. • 10% (HK$703.35 million): selective strategic investments and acquisitions. • 5% (HK$351.70 million): working capital and general corporate purposes.

Completion, slated for 13 July 2026, is conditional on Hong Kong listing approval, PRC regulatory clearances and customary market-out clauses. The company has agreed to a 90-day lock-up on further equity issuance, excluding the current placement and any H-share awards under its existing scheme.

Iluvatar CoreX raised HK$3.51 billion from its January 2026 Hong Kong IPO, with HK$2.47 billion of those funds unspent as of 31 May 2026. Management cites surging domestic demand for AI computing and heightened supply-chain requirements as drivers for the additional capital raise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment